Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.42 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.40 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.35 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | NPY1R | P25929 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6583060 | 0.95 | KMT2A (0.41) | CYP4F2CYP4A11KMT2AMEN1POLB | |
| SCHEMBL6585889 | 0.81 | CYP4F2 (0.64) | CYP4F2CYP4A11ITGB1ITGA4 | |
| SCHEMBL22098179 | 0.81 | CYP4F2 (0.63) | CYP4F2CYP4A11KMT2AMEN1POLB | |
| SCHEMBL8071102 | 0.80 | CYP4F2 (0.45) | CYP4F2CYP4A11KMT2AMEN1POLB | |
| SCHEMBL1106769 | 0.80 | CYP4F2 (0.45) | CYP4F2CYP4A11KMT2AMEN1POLB | |
| SCHEMBL186582 | 0.80 | CYP4F2 (0.45) | CYP4F2CYP4A11KMT2AMEN1POLB | |
| SCHEMBL187550 | 0.80 | CYP4F2 (0.45) | CYP4F2CYP4A11KMT2AMEN1POLB | |
| SCHEMBL186204 | 0.80 | CYP4F2 (0.45) | CYP4F2CYP4A11KMT2AMEN1POLB | |
| SCHEMBL6580602 | 0.79 | ITGB1 (0.40) | CYP4F2CYP4A11LMNAALDH1A1ITGB1 | |
| SCHEMBL798044 | 0.78 | CYP4F2 (0.53) | CYP4F2CYP4A11KMT2AMEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1154993-B1 | THIOAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2004-10-06 | — | — | EP | disclosed |
| US-6479666-B2 | ANTIINFLAMMATORY AGENTS | HOFFMAN-LA ROCHE INC. | 2002-11-12 | — | — | US | disclosed |
| US-6458844-B2 | ANTIINFLAMMATORY AGENTS | HOFFMANN-LA ROCHE INC. | 2002-10-01 | — | — | US | disclosed |
| US-6426348-B1 | FOR THERAPY OF INFLAMMATION ASSOCIATED WITH CHRONIC INFLAMMATORY DISEASES SUCH AS RHEUMATOID ARTHRITIS (RA), MULTIPLE SCLEROSIS, (MS), ASTHMA, AND INFLAMMATORY BOWEL DISEASE (I BD) | HOFFMANN-LA ROCHE INC. | 2002-07-30 | — | — | US | disclosed |
| US-6423728-B1 | INHIBIT BINDING OF VASCULAR CELL ADHESION MOLECULE-1 (VCAM-1) TO THE INTEGRIN VLA-4; USE AS ANTIINFLAMMATORY AGENTS AGAINST RHEMATOID ARTHRITIS, MULTIPLE SCLEROSIS, INFLAMMATORY BOWEL DISEASE AND ASTHMA | HOFFMAN-LA ROCHE INC. | 2002-07-23 | — | — | US | disclosed |
| US-20020052508-A1 | Heterocyclic thioamide derivatives | HULL KENNETH G (US) | 2002-05-02 | — | — | US | disclosed |
| US-20020040148-A1 | Diphenyl heterocyclic thioamide derivatives | HULL KENNETH G (US) | 2002-04-04 | — | — | US | disclosed |
| US-20020028933-A1 | Thioamide derivatives | HULL KENNETH GREGORY (US) | 2002-03-07 | — | — | US | disclosed |
| US-20020010338-A1 | PHENYL-KETO-IMIDAZOLIDINE THIOAMIDE DERIVATIVES | HULL KENNETH G (US) | 2002-01-24 | — | — | US | disclosed |
| EP-1154993-A1 | THIOAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-11-21 | — | — | EP | disclosed |
| US-20010041799-A1 | Diephenyl carbocyclic thioamide derivatives | HULL KENNETH G (US) | 2001-11-15 | — | — | US | disclosed |
| US-6288267-B1 | AROMATIC CARBOXY THIOAMIDES WITH AMIDES AS DRUGS TO COUNTERACT INFLAMMATION | HOFFMANN-LA ROCHE INC. | 2001-09-11 | — | — | US | disclosed |
| WO-2000048994-A1 | THIOAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028933-A1 | Thioamide derivatives | VCAM1, ICAM1, LTB4R | CYP4F2 589/4885CYP4A11 399/4885KMT2A 1104/4885 |
| US-20020010338-A1 | PHENYL-KETO-IMIDAZOLIDINE THIOAMIDE DERIVATIVES | VCAM1, ICAM1, KCNA4 | CYP4F2 1188/4885CYP4A11 464/4885KMT2A 275/4885 |
| US-20020040148-A1 | Diphenyl heterocyclic thioamide derivatives | VCAM1, ICAM1, LTB4R | CYP4F2 665/4885CYP4A11 320/4885KMT2A 1148/4885 |
| US-20010041799-A1 | Diephenyl carbocyclic thioamide derivatives | VCAM1, ICAM1, LTB4R | CYP4F2 693/4885CYP4A11 291/4885KMT2A 1171/4885 |
| US-20020052508-A1 | Heterocyclic thioamide derivatives | VCAM1, ICAM1, LTB4R | CYP4F2 514/4885CYP4A11 332/4885KMT2A 603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.